Health

Promising results for AstraZeneca’s new drug in extending the life of patients with advanced stomach cancer

Positive results for AstraZeneca’s drug against stomach cancer

Results from an advanced clinical trial announced by the Anglo-Swedish pharmaceutical company “AstraZeneca” show that its new experimental drug has helped patients with advanced stomach cancer live longer. According to data presented during the European Society for Medical Oncology conference in Madrid, the median overall survival reached ten months in patients who received the experimental treatment, compared to only five months in those who underwent traditional chemotherapy.

Mechanism of action and mortality risk reduction

The drug is named “Sonesatug Vedotin”, abbreviated as “SON-V”, and belongs to the class of antibody-drug conjugates. This technology relies on linking an antibody with an anti-cancer agent to deliver the treatment directly to target cells with greater precision. Data indicated that the use of this drug was associated with a 53 percent relative reduction in the risk of death compared to the physician’s choice of chemotherapy.

Study details and target groups

The study involved 532 patients suffering from stomach and esophageal cancers who had previously received at least two lines of treatment. The study required the presence of proteins known as “Claudin 18.2” in at least 25 percent of tumor cells. Susan Galbraith, Executive Vice President of Oncology and Hematology R&D at the company, stated that these results are of significant clinical importance for hard-to-treat cases.

Additional indicators and future challenges

Despite the notable improvement in overall survival, the trial did not achieve all its primary endpoints regarding progression-free survival, recording 4.2 months for the group that received the drug compared to 3.8 months for chemotherapy. The company intends to continue research and study the use of the drug in earlier stages, amid mixed commercial expectations and future prospects for collaboration with other biopharmaceutical companies.

Related Articles

💬 Share your opinion

We welcome constructive opinions and ask you to maintain politeness.

0 comments

Leave a Comment

Back to top button